Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3426 | SARS-CoV-2 antibody immunoassays Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
COVID-19 is a disease with high rate of morbidity if symptomatic. There is a great need of treatments to decrease the severity. The vast majority of patients needing intensive care are men, and this may be due to the androgens, either by regulation of TMPRSS2, necessary for virus internalization, or other mechanisms. Enzalutamide is an antiandrogen inhibiting the expression of androgen regulated proteins, such as TMPRSS2. The aim of this trial is to evaluate a possible beneficial effect of short-term enzalutamide treatment of COVID-19 patients.
Description: Clinical worsening to invasive mechanical ventilation or death as assessed by the 7-point ordinal scale
Measure: Time to worsening of disease Time: Up to 30 days after inclusionDescription: Time to discharge from hospital assessed by the 7-point ordinal scale
Measure: Time to improvement of disease Time: Up to 30 days after inclusionDescription: Safety evaluation, as measured by AEs
Measure: Adverse events Time: Up to 6 monthsDescription: Total days of extra oxygen
Measure: Duration of supplemental oxygen (days) Time: Up to 30 daysDescription: Frequence of admission to ICU
Measure: Admission to ICU Time: Up to 30 days and up to 6 monthsDescription: Changes of laboratory parameters: Hb
Measure: Laboratory assessment of Hemoglobin concentration day 0, 2, 4 and 6 Time: Up to 30 daysDescription: PCR based SARS-CoV-2 measurement from upper respiratory tract
Measure: Virus load assessment day 0, 2, 4 and 6 Time: UP to 7 daysDescription: Total number of days evaluated at 30 days and 6 months
Measure: Hospital stay (days) Time: Up to30 days and 6 monthsDescription: If admitted to hospital due to COVID-19 disease after discharge from hospital
Measure: Re-admission to hospital due to rebound COVID-19 Time: Evaluated for 30 days and after 6 monthsDescription: Death due to any cause
Measure: Mortality at 6 months Time: up to 30 days and up to 6 months respectivelyDescription: Testosterone and estrogen levels
Measure: Hormonal status at 6 months Time: from baseline to 6 monthsDescription: Identification of serologic immunity based after 6 months from inclusion
Measure: Serological immunity for COVID-19 Time: At 6 monthsDescription: Changes of laboratory parameters: CRP
Measure: Laboratory assessment of CRP concentration day 0, 2, 4 and 6 Time: Up to 30 daysDescription: Changes of laboratory parameters: ALAT, ASTA and/or ALP
Measure: Laboratory assessment of liver function day 0, 2, 4 and 6 Time: Up to 30 daysDescription: Changes of laboratory parameters: Createnin
Measure: Laboratory assessment of creatinine concentration day 0, 2, 4 and 6 Time: Up to 30 daysDescription: Changes of laboratory parameters: D-dimer
Measure: Laboratory assessment of D-dimer concentration day 0, 2, 4 and 6 Time: Up to 30 daysDescription: Changes of laboratory parameters: TPK
Measure: Laboratory assessment of platelets concentration day 0, 2, 4 and 6 Time: Up to 30 daysDescription: Changes of laboratory parameters: IL-6
Measure: Laboratory assessment of IL-6 concentration day 0, 2, 4 and 6 Time: Up to 30 daysDescription: Changes of laboratory parameters: Differentiate count of leucocytes
Measure: Laboratory assessment of B- and T-lyphocytes concentration day 0, 2, 4 and 6 Time: Up to 30 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports